Immunocompromised; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNODEFICIENCY (Immunocompromised) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products IBRUTINIB (IMBRUVICA) tablet for Mantle cell lymphoma and COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) for COVID-19 vaccination.    No Medical History information was reported.   On 01-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 01-Jun-2021, the patient received third dose of COVID-19 VACCINE NRVV AD26 (JNJ 78436735) (JANSSEN COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, the patient started IBRUTINIB (IMBRUVICA) (Oral) 560 milligram once a day. On an unknown date, the patient experienced IMMUNODEFICIENCY (Immunocompromised). At the time of the report, IMMUNODEFICIENCY (Immunocompromised) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Blood immunoglobulin A: low (Low) Low. On an unknown date, Blood immunoglobulin E: low (Low) Low. On an unknown date, Blood immunoglobulin G: low (Low) Low. On an unknown date, Blood immunoglobulin M: low (Low) Low.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The concomitant medication was not reported by reporter. It was reported that patient did not have covid antibody response following vaccination. The vaccine response was impaired. It was unknown If patient was enrolled in a covid-19 vaccine trial. The treatment medication was not reported by reporter. Company comment: This spontaneous case concerns a male patient of unknown age with no reported medical history, who experienced the unexpected, non-serious event of Immunodeficiency. The exact date of onset of the event was not specified in respect to administration of first and second dose of mRNA-1273. The interval between the two doses is 29 days, the third dose of Janssen was administered 3 months later. On an unknown date, Immunoglobulin panel test was done with low results. It has been reported that patient did not have covid antibody response following vaccination, the vaccine response was impaired. Details of concomitant medications, clinical course, treatment and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This spontaneous case concerns a male patient of unknown age with no reported medical history, who experienced the unexpected, non-serious event of Immunodeficiency. The exact date of onset of the event was not specified in respect to administration of first and second dose of mRNA-1273. The interval between the two doses is 29 days, the third dose of Janssen was administered 3 months later. On an unknown date, Immunoglobulin panel test was done with low results. It has been reported that patient did not have covid antibody response following vaccination, the vaccine response was impaired. Details of concomitant medications, clinical course, treatment and outcome were not provided. The benefit-risk relationship of mRNA-1273 is not affected by this report.